Oct 24 (Reuters) - GENEURO SA GNRO.PA :
* CASH POSITION OF EUR 12.9 MILLION AT 30 SEPTEMBER 2018
* POSITIVE 6-MONTH DATA FROM PHASE IIA STUDY OF GNBAC1 IN
ADULTS
SUFFERING FROM TYPE-1 DIABETES
* CONFIRMED POTENTIAL OF NOVEL HERV-K ANTIBODIES IN TREATING
ALS,
IN COLLABORATION WITH NINDS, WITH ASSOCIATED GLOBAL DEVELOPMENT
RIGHTS SECURED
* OPERATING AND INVESTING ACTIVITIES CONSUMED EUR 4.24
MILLION OF
CASH IN Q3 OF 2018, AS OPPOSED TO AN AVERAGE OF EUR 4.5 MILLION
PER QUARTER IN FIRST HALF OF 2018
* COMPANY DID NOT RECOGNISE ANY REVENUE FROM OPERATING
ACTIVITIES
IN Q3
Source text for Eikon: ID:nBw22JJyja
Further company coverage: GNRO.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))